Increased thyroid malignancy in patients with primary hyperparathyroidism

Luchuan Li1,*, Baoyuan Li2,*, Bin Lv1, Weili Liang1, Binbin Zhang1, Qingdong Zeng1, Andrew G Turner3 and Lei Sheng1

1Department of Thyroid Surgery, General Surgery, Qilu Hospital of Shandong University, Jinan, Shandong, China
2Department of Thyroid Surgery, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China
3Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia

Correspondence should be addressed to L Sheng: lei.sheng@sdu.edu.cn

*(L Li and B Li contributed equally to this work)

Abstract

Background: Multiple studies have reported the increased incidence of thyroid cancer in patients with primary hyperparathyroidism (PHPT). However, the underlying risk factors of concomitant thyroid cancer in patients with PHPT remain unknown. The primary aim of this study was to examine the records of patients with PHPT to identify characteristics that correlated with the presence of coexisting thyroid nodules, and which may have an implication for the prediction of thyroid cancer.

Methods: Medical records of consecutive patients with PHPT (n = 318) were reviewed from January 2010 to September 2020 in two tertiary medical centers in China. Patient clinicopathological and biological data were collected and analyzed.

Results: Of a total of 318 patients with PHPT, 105 (33.0%) patients had thyroid nodules and 26 (8.2%) patients were concomitant with thyroid cancer. A total of 38 thyroid nodules taken from 26 patients were pathologically assessed to be well-differentiated papillary thyroid carcinoma (PTC), with 81% being papillary thyroid microcarcinoma (PTMC). In 79% (30/38) of these cancers, thyroid nodules were considered suspicious following preoperative ultrasound. Multinomial logistic regression analysis revealed that female gender was associated with increased risk of thyroid nodules (OR = 2.13, 95% CI: 1.13–3.99, P = 0.019), while lower log-transformed parathyroid hormone levels were an independent predictor of thyroid cancer in patients with PHPT (OR = 0.50, 95% CI: 0.26–0.93, P = 0.028).

Conclusion: In conclusion, we observed a relatively high prevalence of thyroid cancer in our cohort of Chinese patients with PHPT. Evaluation of thyroid nodules by preoperative ultrasound may be advisable in patients with PHPT, particularly for females and patients with modestly elevated serum parathyroid hormone levels.

Introduction

Primary hyperparathyroidism (PHPT) is a common endocrine disorder, having a prevalence of 0.04–0.1% in the general population (1). The principal role of parathyroid hormone (PTH) is to maintain (raise) blood calcium levels in three different ways: (i) release of calcium from the bones via stimulation of osteoclastic activity; (ii) decrease calcium excretion in the kidney; (iii) increase absorption of calcium from the gut (2). However persistent overproduction of PTH in patients with PHPT may damage target organs including bone and kidney, manifesting...
as osteoporosis and kidney stones (3). A smaller number of patients may present with acute pancreatitis, gastrointestinal ulcers, or neuropsychiatric symptoms (3, 4). Some studies have also reported an increased risk of malignancies, including hematopoietic, breast, skin, thyroid, and urinary tract carcinoma (5, 6, 7). Previous studies have reported 15–75% of patients with PHPT have concomitant thyroid nodules (8, 9). Moreover, several authors have described a rate of thyroid cancer in patients with PHPT that appears to be higher than the general population (4, 10, 11, 12, 13, 14, 15). A review of data from nine studies, including a total of 2510 patients with PHPT requiring parathyroidectomy, indicated an incidence for thyroid cancer of 5%, compared to international estimates ranging from ~2 to 12 per 100,000 thyroid cancer new cases per year (15). Accordingly, patients with PHPT may be at higher risk of thyroid cancer and the detection of thyroid nodules may be treated with greater suspicion. Although elusive at this time, a more detailed understanding of the risk factors contributing to this pathology would benefit clinical decision-making.

The primary aim of this retrospective study was to explore risk factors for malignancy among a cohort of 318 patients with PHPT, with or without benign or malignant thyroid nodules, presenting to two tertiary medical centers in China between 2010 and 2020.

Materials and Methods

Patients

Clinical data were collected from patients with PHPT undergoing surgery in two large tertiary medical centers (Qilu hospital of Shandong University and the Affiliated Yantai Yuhuangding Hospital of Qingdao University) from January 2010 to September 2020. Patients with confirmed PHPT based on medical history, physical examination, and laboratory tests were eligible for inclusion. All parathyroid lesions were pathologically confirmed as either parathyroid adenoma, parathyroid carcinoma or parathyroid hyperplasia. Patients who had secondary or tertiary HPT, multiple endocrine neoplasia, a history of radiation exposure, and those with familial HPT were excluded from this study. Patients with PHPT diagnosed during the clinical work-up for thyroid nodules were also excluded. This study protocol was reviewed and approved by the Qilu Hospital and Yuhuangding Hospital Ethics Committees. Individual informed patient consent was waived due to the retrospective nature of this study.

Data collection

The data for patients with PHPT included age, gender, chronic disease history (hypertension, diabetes mellitus, and coronary heart diseases), PHPT-related comorbidity (urinary tract stones, osteoporosis, pathological fracture, pancreatitis, etc.), laboratory blood analyses within 1 week prior to surgery (PTH, calcium, 25-hydroxyvitamin D (25(OH)D), albumin, phosphorus, potassium, alkaline phosphatase (AKP), creatinine (Cr), blood urea nitrogen (BUN), thyroid-stimulating hormone (TSH), and thyroid autoantibodies (TPOAb and TgAb)). The reference range of PTH was from 15 to 65 pg/mL. Normality of serum calcium was from 2.11 to 2.52 mmol/L. Serum calcium concentrations were adjusted for serum albumin. Adjusted calcium = 0.02 (40 g/L – serum albumin (g/L)) + measured total serum calcium (mmol/L). All patients underwent preoperative thyroid and parathyroid ultrasound imaging. Surgical options were appropriately chosen according to the 2015 American Thyroid Association guideline. Either partial, subtotal, or near-total thyroidectomy was performed for benign thyroid nodules. Where thyroid cancer was confirmed by frozen section or fine-needle aspiration biopsy (FNAB), lobectomy, near-total, or total thyroidectomy with cervical lymph node dissection was performed. Histopathological sections of parathyroid gland and thyroid nodules were reviewed by two independent pathologists. Notably, final pathological reports of thyroid cancer included the following details: tumor size, histological type, location, bilaterality, multifocality, status of extrathyroidal extension, and cervical lymph node metastasis.

Statistical analysis

Statistical analyses were performed using SPSS (version 23.0; SPSS Inc). Continuous variables were presented as mean ± S.D. for normally distributed data or median (minimum to maximum) for non-normally distributed data except for PTH. Due to its skewed distribution, PTH was also reported as natural log-transformed values (lnPTH) when analyzed as continuous quantities. All categorical variables were presented as proportions. Comparisons of means and proportions were performed with independent samples one-way ANOVA and the chi-square test, respectively. Non-normally distributed variables were compared using the Mann–Whitney U-test or Kruskal–Wallis test. Multinomial logistic regression analysis was used to identify potential risk factors for thyroid nodules, including thyroid cancer and benign thyroid nodules, in patients with PHPT. Odds
ratios (OR) and the corresponding 95% CI were calculated for risk factors. A receiver operating characteristic (ROC) analysis was performed to determine the capacity of the clinical and biochemical markers to predict thyroid malignancy in patients with PHPT. A value of $P < 0.05$ was considered as statistically significant.

**Results**

The inclusion process of patients with PHPT was shown in **Fig. 1**. A total of 318 patients with PHPT were included in this study. The mean age was 53 ± 13 years with 70.8% ($n = 225$) of patients being female. Diagnosis with PHPT was initially based on elevated serum calcium or the presence of parathyroid nodules, primarily evident through regular health check-ups ($n = 130$, 41%), followed by urinary tract stones ($n = 79$, 25%), musculoskeletal pain ($n = 62$, 19%), nausea or vomiting ($n = 30$, 9%), fracture ($n = 11$, 3%), pancreatitis ($n = 3$, 1%) (**Fig. 2**). The diagnosis of PHPT was always confirmed by biochemical profile, parathyroid ECT (Emission CT) and ultrasound imaging. The baseline demographic and clinical and biochemical characteristics are described in **Table 1**. Age was comparable between patients with thyroid cancer, benign thyroid nodules, or without thyroid nodules (**Table 1**). Although elevated compared to the normal range (15–65 pg/mL), serum PTH levels were significantly lower in patients with thyroid cancer than patients without thyroid nodules. A larger proportion of female patients with PHPT had thyroid nodules compared to those without thyroid nodules. There were no differences observed in serum calcium, phosphorus, potassium, AKP, BUN, TSH, 25(OH)D levels, TPOAb positivity, and TgAb positivity (**Table 1**).

A histopathologic report confirmed the diagnosis in all cases with the final diagnosis of PHPT being parathyroid adenoma in 282 patients (88.68%), atypical parathyroid adenoma in 22 patients (6.92%), oncocytic parathyroid adenoma in 2 patients (0.63%), parathyroid carcinoma in 8 patients (2.52%), and parathyroid hyperplasia in 4 patients (1.26%). Of the total of 318 patients with PHPT, 105 (33.0%) patients had thyroid nodules and 26 (8.2%) patients were concomitant with thyroid cancer (**Table 2**). Of these 26 cases, all were assessed to be well-differentiated papillary thyroid carcinoma (PTC), namely 21 cases (81%) of papillary thyroid microcarcinoma (PTMC), 3 cases (12%) of conventional PTC, and 2 cases (7%) of a tall-cell variant of PTC (**Table 3**). Bilaterality, multifocality, extrathyroidal extension, and central lymph node metastasis were found in 7 cases (26.9%), 8 cases (30.8%), 8 cases (30.8%), and 2 cases (7.7%), respectively. Among the 26 patients, a total of 38 malignant thyroid nodules were ultimately confirmed by pathology. Prior to surgery, 30 (79%) hypoechoic thyroid nodules were observed as suspicious by preoperative ultrasound, while 8 (21%) thyroid nodules were neither detected nor suspicious as malignancy by ultrasound (Supplementary Table 1, see section on supplementary materials given at the end of this article).

To further investigate the factors associated with benign thyroid nodules and thyroid cancer being present...
The clinical pattern leading to patients initially being diagnosed with PHPT. Regular health check-ups (n = 130, 41%); urinary tract stones (n = 79, 25%); musculoskeletal pain (n = 62, 19%); nausea and vomiting (n = 30, 9%); fracture (n = 11, 3%); pancreatitis (n = 3, 1%); others (n = 3, 1%).

in patients with PHPT, multivariate-adjusted logistic regression analyses were performed. Female gender was an independent predictor for thyroid nodules after adjusting for lnPTH (model 1), age, albumin-adjusted serum calcium, and creatinine (model 2). The presence of thyroid cancer was significantly associated with decreased of lnPTH (OR=0.52; 95% CI: 0.32–0.84; P = 0.008) after adjusting for gender (model 1). The association remained significant after additional adjustment for age, albumin-adjusted serum calcium and creatinine (OR=0.50; 95% CI: 0.26–0.93; P=0.028) (model 2) (Table 4). The ROC analysis revealed that serum PTH levels < 192 pg/mL had a good capacity to differentiate the thyroid malignancy from benign thyroid nodules or without thyroid nodules, with an area under the curve (AUC) of 0.687 (P=0.002). This cut-off value for the PTH level had a sensitivity of 69.2% and a specificity of 67.8% for predicting thyroid malignancy in patients with PHPT.

Discussion

The coexistence of thyroid disease in patients with PHPT is a known clinical challenge that remains poorly understood, with highly variable incidence rates being reported and potential risk factors being unclear. The prevalence of thyroid nodules in our cohort of patients with PHPT was 33.0%, being similar to other populations (20–76%) (16, 17). The proportion of female patients with PHPT having thyroid nodules was significantly higher than those without thyroid nodules and is also consistent with epidemiological findings suggesting females are more prone to developing thyroid nodules (18, 19). Our data did not reflect any differences in gender distribution between patients with thyroid cancer and patients with benign thyroid nodules.

To the best of our knowledge, this was the largest cohort study of thyroid cancer in patients with PHPT in China. The incidence of thyroid cancer we observed in patients with PHPT was 8.2%, similar to two previous Chinese studies that have reported prevalence rates of 7.7% (12/155 patients) and 6.3% (7/112 patients) (12, 14). Taken together, these three studies in Chinese populations report a higher rate of malignancy in patients with PHPT than other similar studies. Two reviews have estimated the incidence of thyroid cancer in patients with PHPT by pooling data from multiple countries, reporting average rates of 3.5% (12) and 5% (15). We also observed an overall rate of malignancy of 25% for thyroid nodules in patients with PHPT, which is higher than the rate reported in the general population with thyroid nodules (7–15%) (20). Noting the highly variable nature of data in this field, these results suggest a higher rate of malignancy in our cohort compared to other similar studies, warranting some discussion of the possible contributing factors. It is striking that the average serum level of 25(OH)D we observed was 10.67 ± 6.34 ng/mL (~25 nmol/L). Such values are not uncommon among clinical populations in China but are approximately half the commonly agreed minimum target level for vitamin D sufficiency (21). To our knowledge, vitamin D status has not been reported in other studies to allow comparison with other cohorts of patients with PHPT. Perhaps significantly, vitamin D deficiency has been increasingly implicated in the initiation and progression of numerous malignancies. However, as with other cancers, the hypothesis that vitamin D status modulates thyroid cancer incidence is equivocal (22). Nevertheless, an analysis of preoperative serum 25(OH)D levels in 548 females undergoing thyroidectomy has revealed lower 25(OH)D levels in patients with a tumor size > 1 cm (23).

Several studies have explored the potential role of elevated PTH and calcium levels in thyroid diseases in patients with PHPT but have reported conflicting results (3, 14). One previous study involving a total of 59 PHPT cases indicated that high PTH levels were significantly associated with the development of thyroid cancer (3), while another two studies found no correlation between thyroid cancer and serum PTH levels (14, 24). In contrast, we have observed in our relatively large patient cohort that preoperative serum PTH levels were significantly lower in patients with thyroid cancer than in patients without thyroid nodules. Furthermore, a low value for log-transformed PTH was found to be an independent predictor for the presence

Figure 2
The clinical pattern leading to patients initially being diagnosed with PHPT. Regular health check-ups (n = 130, 41%); urinary tract stones (n = 79, 25%); musculoskeletal pain (n = 62, 19%); nausea and vomiting (n = 30, 9%); fracture (n = 11, 3%); pancreatitis (n = 3, 1%); others (n = 3, 1%).

https://ec.bioscientifica.com
https://doi.org/10.1530/EC-21-0217
of thyroid cancer in patients with PHPT after adjusting for other confounding factors. A possible correlation between serum calcium levels and various cancers in the general population, such as colorectal and breast, remains controversial (25, 26, 27). One study from a Chinese group found a significant negative correlation between the albumin-corrected serum calcium level and the presence of thyroid cancer in patients with PHPT (14). Our data suggest adjusted serum calcium levels may be lower in PHPT patients with thyroid cancer, although no statistical difference was observed compared to patients with benign nodules, or without nodules (P = 0.129). A small cross-sectional study consisting of 40 medullary thyroid cancer patients and 40 healthy controls showed a low serum calcium level was a potent risk factor for medullary thyroid cancer (28). And a case-control study including 1092 participants, indicated that lower serum calcium levels were an independent predictor of thyroid nodules among patients with type 2 hyperparathyroidism; PTH, parathyroid hormone; TgAb, thyroglobulin antibody; TPOAb, thyroid peroxidase antibody; TSH, thyroid-stimulating hormone.

| Table 1 | Clinical and biologic characteristics between PHTP with and without benign or malignant thyroid nodules. |
|---------|---------------------------------------------------------------|
|         | Total PHPT (n = 318) | Thyroid carcinoma (n = 26) | Benign thyroid nodule (n = 79) | Without thyroid nodules (n = 213) |
| Age     | 53 ± 13             | 53 ± 7                     | 56 ± 10<sup>a</sup>           | 52 ± 14                        |
| Sex     |                      |                            |                               |                               |
| Male    | 93 (29.2%)          | 4 (15.4%)                  | 15 (19.0%)                    | 74 (34.7%)                     |
| Female  | 225 (70.8%)         | 22 (84.6%)<sup>b</sup>     | 64 (81.0%)<sup>b</sup>        | 139 (65.3%)                    |
| Comorbidity        |                  |                            |                               |                               |
| Hypertension   | 85 (26.7%)         | 7 (26.9%)                  | 21 (26.6%)                    | 57 (26.8%)                     |
| Diabetes mellitus | 27 (8.5%)          | 1 (3.8%)                   | 7 (8.9%)                      | 19 (9.8%)                      |
| Coronary heart disease | 22 (6.9%) | 1 (3.8%) | 6 (7.6%) | 15 (7.0%) |
| Urinary tract stones | 99 (31.1%) | 4 (15.4%)<sup>b</sup> | 14 (17.7%)<sup>b</sup> | 81 (38.0%) |
| Osteoporosis   | 60 (18.9%)         | 15 (57.7%)                 | 21 (26.6%)                    | 35 (16.4%)                     |
| Pathological fracture | 11 (3.5%) | 1 (3.8%) | 1 (1.3%) | 9 (4.2%) |
| Pancreatitis   | 3 (0.9%)           | 0 (0.0%)                   | 2 (2.5%)                      | 1 (0.5%)                       |
| Malignant tumor history | 10 (3.1%) | 1 (3.8%) | 4 (5.1%) | 5 (2.3%) |
| Gastrointestinal ulcer | 1 (0.3%) | 0 (0.0%) | 0 (0.0%) | 1 (0.5%) |
| Biological features |                  |                            |                               |                               |
| PTH (pg/mL)    | 284.9 (30.63–5000.0) | 143.85 (30.6–3576.0)<sup>c</sup> | 275.3 (73.15–3545.0) | 336.0 (65.8–5000.0) |
| InPTH          | 5.88 ± 1.05        | 5.34 ± 1.19<sup>b</sup>    | 5.81 ± 0.95                   | 5.97 ± 1.04                    |
| Serum calcium (mmol/L) | 3.02 ± 0.48 | 2.93 ± 0.45 | 2.95 ± 0.49 | 3.06 ± 0.47 |
| Adjusted serum calcium (mmol/L) | 2.97 ± 0.50 | 2.86 ± 0.47 | 2.90 ± 0.50 | 3.01 ± 0.49 |
| Serum phosphorus (mmol/L) | 0.79 ± 0.24 | 0.81 ± 0.17 | 0.82 ± 0.31 | 0.77 ± 0.21 |
| Serum potassium (mmol/L) | 4.11 ± 0.49 | 4.10 ± 0.46 | 4.14 ± 0.50 | 4.10 ± 0.49 |
| AKP (U/L)      | 125 (22–2540)      | 99 (56–734)                | 119 (53–1447)                 | 136 (22–2540)                  |
| Cr (μmol/L)    | 69.36 ± 36.41      | 65.22 ± 22.70              | 61.87 ± 31.19<sup>c</sup>    | 72.65 ± 39.10                  |
| BUN (mmol/L)   | 5.05 ± 2.50        | 4.44 ± 1.55                | 4.81 ± 2.61                   | 5.21 ± 2.54                    |
| TSH (μU/mL)    | 1.66 (0.003–25.59) | 2.21 (0.003–4.43)          | 1.87 (0.006–6.33)             | 1.50 (0.05–25.59)              |
| 25(OH)D (ng/mL)<sup>c</sup> | 10.67 ± 6.34 (135) | 12.46 ± 7.28 (14) | 10.25 ± 5.65 (28) | 10.53 ± 6.42 (93) |
| TPOAb positivity<sup>c</sup> | 26.6% (53/199) | 25.0% (5/20) | 28.1% (16/57) | 26.2% (32/122) |
| TgAb positivity<sup>c</sup> | 32.5% (63/194) | 35.0% (7/20) | 31.6% (18/57) | 32.5% (38/117) |

<sup>a</sup>P value < 0.05 as compared to patients with PHPT without thyroid nodules; <sup>b</sup>P value < 0.01 as compared to patients with PHPT without thyroid nodules; <sup>c</sup>Data were available in a smaller cohort and number of cases with available data are listed in brackets.

Table 2 | Association of benign and malignant thyroid nodules with PHPT. |
|---------|---------------------------------------------------------------|
|         | Total (n = 318) (%) | Not concomitant with thyroid nodules (n = 213) (%) | Concomitant with thyroid nodules | |
| Parathyroid adenoma | 282 (88.68) | 184 (86.38) | |
| Atypical parathyroid adenoma | 22 (6.92) | 19 (8.92) | |
| Oncocytic parathyroid adenoma | 2 (0.63) | 2 (0.94) | |
| Parathyroid carcinoma | 8 (2.52) | 7 (3.29) | |
| Parathyroid hyperplasia | 4 (1.26) | 1 (0.47) | |

Downloaded from Bioscientifica.com at 09/14/2023 11:07:09AM via free access
Table 3 Characteristics of patients with PHPT and thyroid carcinoma.

| Case | Age | Sex  | Location of tumor | Number of tumor | Tumor type       | Tumor size (cm) | PTH (pg/mL) | Extrathyroidal extension | Central lymph node metastasis |
|------|-----|------|-------------------|----------------|-----------------|----------------|-------------|-------------------------|-------------------------------|
| 1    | 53  | Female | Left              | 2              | PTMC            | 0.4, 0.1       | 1813.0      | No                      | No (0/5)                      |
| 2    | 55  | Female | Left              | 1              | Conventional PTC| 1.1            | 77.1        | Yes                     | No (0/10)                     |
| 3    | 63  | Male   | Right             | 1              | PTMC            | 0.4            | 321.3       | No                      | No (0/3)                      |
| 4    | 43  | Female | Left              | 1              | PTMC            | 0.8            | 1039.0      | No                      | No (0/6)                      |
| 5    | 54  | Female | Bilateral         | 2              | PTMC            | 0.5, 0.6       | 66.1        | Yes                     | Yes (2/10)                    |
| 6    | 57  | Female | Right             | 1              | PTMC            | 1              | 111.9       | No                      | No (0/2)                      |
| 7    | 44  | Male   | Left              | 1              | PTMC            | 0.7            | 3576.0      | No                      | No (0/2)                      |
| 8    | 52  | Male   | Left              | 1              | PTMC            | 0.5            | 396.5       | No                      | No (0/6)                      |
| 9    | 45  | Female | Bilateral         | 2              | Conventional PTC| 0.6, 1.5       | 115.8       | Yes                     | Yes (6/12)                    |
| 10   | 63  | Female | Bilateral         | 2              | PTMC            | 0.1, 0.4       | 159.2       | No                      | No (0/4)                      |
| 11   | 58  | Female | Bilateral         | 3              | PTMC            | 1.0, 0.7, 0.6  | 190.6       | No                      | NA                            |
| 12   | 41  | Female | Right             | 1              | PTMC            | 0.3            | 1548.0      | No                      | NA                            |
| 13   | 54  | Male   | Left              | 1              | PTMC            | 1              | 1430.0      | No                      | NA                            |
| 14   | 66  | Female | Right             | 1              | PTMC            | 0.9            | 149.9       | Yes                     | No (0/9)                      |
| 15   | 54  | Female | Left              | 1              | Conventional PTC| 1.1            | 103.8       | Yes                     | No (0/15)                     |
| 16   | 43  | Female | Right             | 1              | PTMC            | 0.4            | 30.6        | No                      | NA                            |
| 17   | 47  | Female | Bilateral         | 4              | Tall-cell variant of PTC | 0.6, 0.5, 0.3, 0.06 | 171.2 | Yes | No (0/10) |
| 18   | 67  | Female | Right             | 1              | Tall-cell variant of PTC | 1.3            | 85.3        | Yes                     | No (0/1)                      |
| 19   | 52  | Female | Bilateral         | 3              | PTMC            | 0.6, 0.3, 0.3  | 128.3       | Yes                     | No (0/1)                      |
| 20   | 52  | Female | Right             | 1              | PTMC            | 0.5            | 373.2       | No                      | No (0/3)                      |
| 21   | 57  | Female | Left              | 1              | PTMC            | 0.4            | 80.7        | No                      | No (0/1)                      |
| 22   | 60  | Female | Right             | 1              | PTMC            | 0.6            | 146.5       | No                      | No (0/6)                      |
| 23   | 52  | Female | Left              | 1              | PTMC            | 0.5            | 141.2       | No                      | No (0/6)                      |
| 24   | 59  | Female | Left              | 1              | PTMC            | 0.5            | 98.2        | No                      | No (0/4)                      |
| 25   | 46  | Female | Bilateral         | 2              | PTMC            | 0.4, 0.3       | 103.6       | No                      | No (0/2)                      |
| 26   | 46  | Female | Left              | 1              | PTMC            | 0.7            | 100.4       | No                      | No (0/2)                      |

ETE, extrathyroidal extension; NA, not available; PHPT, primary hyperparathyroidism; PTC, papillary thyroid cancer; PTMC, papillary thyroid microcarcinoma.

Molecular analyses indicate that mitogen-activated protein kinase (MAPK) pathway activation is crucial for the initiation of PTC, particularly in patients with BRAF V600E mutation or RET/PTC rearrangements (31). In addition, the Wnt/β-catenin signaling pathway plays a critical role in driving the development and progression of PTC by promoting cell proliferation and invasion (32, 33). Previous studies have indicated that PTH exerts antiapoptotic or proliferating actions by activating Wnt/β-catenin or MAPK signaling pathways in osteoblastic cells, demonstrating its mitogenic effects (34, 35). We hypothesize that PTH may potentiate the intrinsic MAPK signaling pathway in patients harboring BRAF V600E mutation or RET/PTC rearrangements. Unfortunately, genetic profiles of patients with PTC included in our study were unavailable.

Currently, there are no guidelines to manage the coexistence of thyroid nodules in patients with PHPT. For thyroid cancer, lobectomy or total thyroidectomy with cervical lymph node dissection is recommended according to 2015 ATA (American Thyroid Association) guidelines (20). For PHPT, the surgical approach has transitioned from bilateral...
Table 4  Risk of thyroid nodules, benign thyroid nodules, and thyroid cancer by serum PTH.

|                     | Model 1, OR (95% CI) | P value | Model 2, OR (95% CI) | P value |
|---------------------|----------------------|---------|----------------------|---------|
| Thyroid nodules (n = 105) |                      |         |                      |         |
| ln (PTH) (1/ln (pg/mL)) | 0.79 (0.62–1.00)    | 0.052   | 0.88 (0.65–1.20)    | 0.884   |
| Women               | 2.39 (1.33–4.30)    |         | 2.13 (1.13–3.99)    | 0.019   |
| Adjusted serum calcium (1/mmol/L) | –               | –       | 0.83 (0.41–1.68)    | 0.609   |
| Cr (1/μmol/L)       | –                    | –       | 1.00 (0.99–1.01)    | 0.222   |
| Age                 | –                    | –       | 1.02 (0.99–1.04)    | 0.102   |
| Benign thyroid nodules (n = 79) |                  |         |                      |         |
| ln (PTH) (1/ln (pg/mL)) | 0.88 (0.68–1.15)    | 0.354   | 1.04 (0.75–1.44)    | 0.835   |
| Women               | 2.31 (1.21–4.43)    |         | 1.98 (0.98–3.98)    | 0.056   |
| Adjusted serum calcium (1/mmol/L) | –               | –       | 0.76 (0.35–1.66)    | 0.490   |
| Cr (1/μmol/L)       | –                    | –       | 0.99 (0.98–1.00)    | 0.132   |
| Age                 | –                    | –       | 1.03 (1.00–1.05)    | 0.038   |
| Thyroid cancer (n = 26) |                   |         |                      |         |
| ln (PTH) (1/ln (pg/mL)) | 0.52 (0.32–0.84)    | 0.008   | 0.50 (0.26–0.93)    | 0.028   |
| Women               | 2.66 (0.87–8.09)    |         | 2.69 (0.83–8.75)    | 0.100   |
| Adjusted serum calcium (1/mmol/L) | –               | –       | 1.25 (0.35–4.50)    | 0.734   |
| Cr (1/μmol/L)       | –                    | –       | 1.00 (0.99–1.02)    | 0.855   |
| Age                 | –                    | –       | 1.00 (0.96–1.03)    | 0.834   |

Multinomial adjusted logistic regression analyses for 318 patients with PHPT. Patients with primary hyperparathyroidism without thyroid nodules were used as a reference group. Model 1 is adjusted for gender. Model 2 is further adjusted for age, creatinine (Cr), and albumin-adjusted serum calcium. ln, natural logarithm; PTH, parathyroid hormone.

Multinomial adjusted logistic regression analyses for 318 patients with PHPT. Patients with primary hyperparathyroidism without thyroid nodules were used as a reference group. Model 1 is adjusted for gender. Model 2 is further adjusted for age, creatinine (Cr), and albumin-adjusted serum calcium. ln, natural logarithm; PTH, parathyroid hormone.

A limitation of this study was that serum PTH and calcium levels were measured at a single point within 1 week prior to surgery, and these data may have varied at other time points. Although the low serum 25(OH) D levels measured in a subset of patients are intriguing, these data were not sufficient to test for an association between vitamin D deficiency and risk of malignancy. Moreover, a small set of patients with asymptomatic PHPT not undergoing surgery were excluded from our analysis, leading to a potential selection bias.

Conclusions

Both benign and malignant thyroid nodules may be commonly encountered in patients with primary hyperparathyroidism. We have observed a relatively high prevalence of thyroid malignancy in our cohort of Chinese patients with PHPT. Our analyses suggest that evaluation of thyroid nodules by preoperative ultrasound is warranted in patients with PHPT, particularly for female patients and those with modestly elevated serum parathyroid hormone levels.

Supplementary materials

This is linked to the online version of the paper at https://doi.org/10.1530/EC-21-0217.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This work was supported by the National Natural Science Foundation of China (Grant No. 81802642; Grant recipient: Lei Sheng) and Shandong Provincial Natural Science Foundation of China (Grant No. ZK2019PH082; Grant recipient: Weili Liang).
Primary hyperparathyroidism

and thyroid cancer

10:8 | 892

Ethics approval

This study protocol was reviewed and approved by the Qilu Hospital Oncology Ethics Committee. Individual informed patient consent was waived due to the retrospective nature of this study.

Author contribution statement

L L, B L, and L S designed the study. B L, W L, Q Z, and B Z collected the data and performed the analyses. All authors discussed the results, wrote and approved the submission of the manuscript.

References

1 Çetin K, Sıkar HE, Temizkan Ş, Oluoğlu CB, Özderya A, Aydin K, Gül AE & Kıcık HE. Does primary hyperparathyroidism have an association with thyroid papillary cancer? A retrospective cohort study. World Journal of Surgery 2019 43 1243–1248. (https://doi.org/10.1007/s00268-019-04920-4)
2 Khundmiri SJ, Murray RD & Lederer E. PTH and vitamin D. Comprehensive Physiology 2016 6 561–601. (https://doi.org/10.1002/cphy.c140071)
3 Vargas-Ortega G, Balcarz-Hernandez L, Gonzalez-Vilba B, Ramirez-Renteria C, Nieto-Guzman O, Garrido-Mendoza AP, Flores-Mayo MA, Mercado M & Victoria MZ. Symptomatic primary hyperparathyroidism as a risk factor for differentiated thyroid cancer. Journal of Thyroid Research 2018 2018 9461079. (https://doi.org/10.1155/2018/9461079)
4 Lehwald N, Cupisti K, Krausch M, Ahrazoglu M, Raffel A & Knoefel WT. Coincidence of primary hyperparathyroidism and nonmedullary thyroid carcinoma. Hormone and Metabolic Research 2013 45 660–663. (https://doi.org/10.1007/s00277-013-14518-4)
5 Pickard AL, Gridley G, Mellemkjaer L, Johansen C, Kofoed-Enevoldsen A, Cantor KP & Brinton LA. Hyperparathyroidism and subsequent cancer risk in Denmark. Cancer 2002 95 1611–1617. (https://doi.org/10.1002/cncr.10846)
6 Nilsson IL, Zedenius J, Yin L & Ekbo A. The association between primary hyperparathyroidism and malignancy: nationwide cohort analysis on cancer incidence after parathyroidectomy. Endocrine-Related Cancer 2007 14 135–140. (https://doi.org/10.1677/erc.1.01261)
7 Palmieri S, Roggero L, Cairoli E, Morelli V, Scillitani A, Chiodini I & Elser-Vainicher C. Occurrence of malignant neoplasia in patients with primary hyperparathyroidism. European Journal of Internal Medicine 2017 43 77–82. (https://doi.org/10.1016/j.ejim.2017.06.001)
8 Morita SY, Somervell H, Umbricht CB, Dackiw AP & Zeiger MA. Evaluation for concomitant thyroid nodules and primary hyperparathyroidism in patients undergoing parathyroidectomy or thyroidectomy. Surgery 2008 144 862–866; discussion 866–868. (https://doi.org/10.1016/j.surg.2008.07.029)
9 Arceiro CA, Shiuie ZS, Gates JD, Peoples GE, Dackiw AP, Tufano RP, Libutti SK, Zeiger MA & Stoeltingnico A. Preoperative thyroid ultrasound is indicated in patients undergoing parathyroidectomy for primary hyperparathyroidism. Journal of Cancer 2012 3 1–6. (https://doi.org/10.7150/jca.3.1)
10 Kosem M, Algun E, Kotan C, Harman M & Ozturk M. Coexistent thyroid pathologies and high rate of papillary cancer in patients with primary hyperparathyroidism: controversies about minimal invasive parathyroid surgery. Acta Chirurgica Belgica 2004 104 566–571. (https://doi.org/10.1080/00015458.2004.1167961)
11 Ogurum P & Black BM. Primary hyperparathyroidism and papillary adenocarcinoma of the thyroid; report of four cases. Proceedings of the Staff Meetings: Mayo Clinic 1966 31 285–298.
12 Shen J, Wu Q & Wang Y. The role of ultrasound in the diagnosis of the coexistence of primary hyperparathyroidism and non-medullary thyroid carcinoma. BMC Medical Imaging 2019 19 7. (https://doi.org/10.1186/s12898-019-0304-6)
13 Linos DA, van Heerden JA & Edis AJ. Primary hyperparathyroidism and nonmedullary thyroid cancer. American Journal of Surgery 1982 143 301–303. (https://doi.org/10.1016/0002-9618(82)90095-2)
14 Xue Y, Ye ZQ, Zhou HW, Shi BM, Yi XH & Zhang KQ. Serum calcium and risk of nonmedullary thyroid cancer in patients with primary hyperparathyroidism. Medical Science Monitor 2016 22 4842–4849. (https://doi.org/10.12659/mds.898938)
15 Cinamon U, Levy D & Marom T. Is primary hyperparathyroidism a risk factor for papillary thyroid cancer? An exemplary study and literature review. International Archives of Otorhinolaryngology 2015 19 42–45. (https://doi.org/10.5651/iaro.2015.19.42)
16 Dean DS & Gharib H. Epidemiology of thyroid nodules. Best Practice and Research: Clinical Endocrinology and Metabolism 2008 22 901–911. (https://doi.org/10.1016/j.beem.2008.09.019)
17 Vanderpump MF. The epidemiology of thyroid disease. British Medical Bulletin 2011 99 39–51. (https://doi.org/10.1093/bmbid/ldr030)
18 Yan HX, Pang F, Wang FL, Tian W, Liao YK, Huang W, Yang QJ, Jin N, Zang L, Du J, et al. Dynamic profile of differentiated thyroid cancer in male and female patients with thyroidectomy during 2000–2013 in China: a retrospective study. Scientific Reports 2017 7 15832. (https://doi.org/10.1038/s41598-017-14963-z)
19 Rahbabi R, Zhang L & Kebebew E. Thyroid cancer gender disparity. Future Oncology 2010 6 1771–1779. (https://doi.org/10.2217/fon.10.127)
20 Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancers. Thyroid 2016 26 1–133. (https://doi.org/10.1089/thy.2015.0020)
21 Kimball SM & Holick MF. Official recommendations for vitamin D through the life stages in developed countries. European Journal of Clinical Nutrition 2020 74 1514–1518. (https://doi.org/10.1038/s41430-020-00706-3)
22 Zhao J, Wang H, Zhang Z, Zhou X, Yao J, Zhang R, Liao L & Dong J. Vitamin D deficiency as a risk factor for thyroid cancer: a meta-analysis of case-control studies. Nutrition 2019 57 5–11. (https://doi.org/10.1016/j.nut.2018.04.015)
23 Kim JR, Kim BH, Kim SM, Oh MY, Kim WJ, Jeon YK, Kim SS, Lee BJ, Kim YK & Kim JI. Low serum 25-hydroxyvitamin D is associated with poor clinicopathologic characteristics in female patients with papillary thyroid cancer. Thyroid 2014 24 1618–1624. (https://doi.org/10.1089/thy.2014.0990)
24 Kutluturk K, Otan E, Yagci MA, Usta S, Aydin C & Ural B. Thyroid pathologies accompanying primary hyperparathyroidism: a high rate of papillary thyroid microcarcinoma. Utsal Cehenni Dergisi 2014 30 125–128. (https://doi.org/10.5152/UCD.2014.2685)
25 Fuszek P, Lakatos F, Tabak A, Papp J, Nagy Z, Takacs I, Horvath HC, Lakatos PL & Speer G. Relationship between serum calcium and CA 19–9 levels in colorectal cancer. World Journal of Gastroenterology 2004 10 1890–1892. (https://doi.org/10.3748/wjg.v10.i13.1890)
26 Almoqit M, Manjer J, Bondeson L & Bondeson AG. Serum calcium and breast cancer risk: results from a prospective cohort study of 7,847 women. Cancer Causes and Control 2007 18 595–602. (https://doi.org/10.1007/s10552-007-9001-0)
27 Wulaningsih W, Michaelsson K, Garmo H, Hammar N, Jungner L, Walladius G, Lambe M, Holmberg L & Van Hemelrijck M. Serum calcium and risk of gastrointestinal cancer in the Swedish AMORIS study. BMC Public Health 2013 13 663. (https://doi.org/10.1186/1471-2458-13-663)
28 Emami A, Nazem MR, Shekarziz R & Hedayati M. Micronutrient status (calcium, vitamin D and E) in patients with medullary thyroid carcinoma: a cross-sectional study. Nutrition 2017 41 86–89. (https://doi.org/10.1016/j.nut.2017.04.004)
29 Bener A, Ozdenkaya Y, Al-Hamaq AOAA, Barisik CC & Ozturk M. Low vitamin D deficiency associated with thyroid disease among type 2 diabetic mellitus patients. *Journal of Clinical Medicine Research* 2018 10 707–714. (https://doi.org/10.14740/jocmr3507w)

30 Preda C, Branisteamn D, Armasu I, Danila K, Velicescu C, Ciobanu D, Covic A & Grigorovici A. Coexistent papillary thyroid carcinoma diagnosed in surgically treated patients for primary versus secondary hyperparathyroidism: same incidence, different characteristics. *BMC Surgery* 2019 19 94. (https://doi.org/10.1186/s12893-019-0556-y)

31 Nikiforov YE & Nikiforova MN. Molecular Genetics and diagnosis of thyroid cancer. *Nature Reviews: Endocrinology* 2011 7 569–580. (https://doi.org/10.1038/nrendo.2011.142)

32 Zhang J, Gill AJM, Issacs JD, Atmore B, Johns A, Delbridge LW, Lai R & McMullen TPW. The Wnt/β-catenin pathway drives increased cyclin D1 levels in lymph node metastasis in papillary thyroid cancer. *Human Pathology* 2012 43 1044–1050. (https://doi.org/10.1016/j.humpath.2011.08.013)

33 Pang R, Xu Y, Hu X, Liu B & Yu J. Vitamin D receptor knockdown attenuates the antiproliferative, pro-apoptotic and anti-invasive effect of vitamin D by activating the Wnt/β-catenin signaling pathway in papillary thyroid cancer. *Molecular Medicine Reports* 2020 22 4135–4142. (https://doi.org/10.3892/mmr.2020.11522)

34 Tobimatsu T, Kaji H, Sowa H, Naito J, Canaff L, Hendy GN, Sugimoto T & Chihara K. Parathyroid hormone increases beta-catenin levels through Smad3 in mouse osteoblastic cells. *Endocrinology* 2006 147 2583–2590. (https://doi.org/10.1210/en.2005-1627)

35 Swarthout JT, Doggett TA, Lemker JL & Partridge NC. Stimulation of extracellular signal-regulated kinases and proliferation in rat osteoblastic cells by parathyroid hormone is protein kinase C-dependent. *Journal of Biological Chemistry* 2001 276 7586–7592. (https://doi.org/10.1074/jbc.M007400200)

36 Chan S, Karamali K, Kooldziejczyk A, Oikonomou G, Watkinson J, Paleri V, Nixon I & Kim D. Systematic review of recurrence rate after hemithyroidectomy for low-risk well-differentiated thyroid cancer. *European Thyroid Journal* 2020 9 73–84. (https://doi.org/10.1159/000504961)

37 Song E, Han M, Oh HS, Kim WW, Jeon MJ, Lee YM, Kim TY, Chung KW, Kim WB, Shong YK, et al. Lobectomy is feasible for 1–4 cm papillary thyroid carcinomas: a 10-year propensity score matched-pair analysis on recurrence. *Thyroid* 2019 29 64–70. (https://doi.org/10.1089/thy.2018.0554)

38 Kwon H, Oh HS, Kim M, Park S, Jeon MJ, Kim WG, Kim WB, Shong YK, Song DE, Baek JH, et al. Active surveillance for patients with papillary thyroid microcarcinoma: a single center’s experience in Korea. *Journal of Clinical Endocrinology and Metabolism* 2017 102 1917–1925. (https://doi.org/10.1210/jc.2016-4026)

39 Molinaro E, Campopiano MC, Pieruzzi L, Matrone A, Agate L, Bottici V, Viola D, Cappagli V, Valerio L, Giani C, et al. Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at one single Italian center. *Journal of Clinical Endocrinology and Metabolism* 2020 105.e172–105.e180. (https://doi.org/10.1210/clinem/dgz113)

Received in final form 4 July 2021
Accepted 14 July 2021
Accepted Manuscript published online 14 July 2021